Peptide CDMOs have entered a phase of scaled competition, with Chinese CRDMO leaders widening their advantages

Overview

This report is the first part of Bernstein's multi-part CDMO primer series, focusing on the supply side of peptide CDMOs. It notes that the peptide CDMO industry remains highly fragmented, but demand for GLP-1 and metabolic peptides is shifting competition toward large-scale capital investment, rapid capacity ramp-up, cost control, and complex peptide technology platforms. Chinese CRDMOs, especially WuXi AppTec and Asymchem, have gained clear share in this expansion cycle.

Core views

The core views are: first, industry growth is gradually shifting from traditional specialized peptide CDMOs toward large CRDMOs with scaled commercial manufacturing capabilities; second, WuXi AppTec has become the strongest current supply-side platform thanks to early capacity expansion, the largest output scale, lower costs, and higher ROIC; third, although Asymchem's peptide business base is smaller, growth accelerated in 2025 and it has the potential to gain future share; fourth, Western specialized peptide companies such as Bachem and PolyPeptide still retain advantages in technology and regulatory track record, but are relatively behind in growth and capital efficiency during the large-scale GLP-1 demand cycle; fifth, Chinese suppliers' shortcomings are insufficient globalized capacity and higher exposure to geopolitical risks.

Analysis framework

The report uses a supply-side competitive framework to compare major global peptide CDMOs across company type, revenue scale, capacity, batch size, capital expenditure, gross margin, EBIT margin, ROIC, technology mix, sustainable processes, and development-to-delivery cycle, and combines this with company-specific valuation methods to derive target prices and ratings.

Methodology notes

• Industry competition analysisComparison of scale, cost, and technology breadth

  Supply-side competitiveness framework for peptide CDMOs

  The report argues that the core differentiators among peptide CDMOs are commercial output scale, batch manufacturing capability, cost structure, capital efficiency, complex conjugation technologies, green processes, and delivery speed, rather than simply reactor volume.

• Valuation methodologyBlended valuation using DCF, P/E, and EV/EBITDA

  Multi-method target price

  For covered companies such as Asymchem and WuXi AppTec, one-year target prices are derived using roughly one-third weight each for DCF, forward P/E, and EV/EBITDA.

• Manufacturing processComparison of SPPS, LPPS, and recombinant production

  Peptide drug manufacturing routes

  The report explains that most modern metabolic peptides use chemical synthesis, typically based on SPPS, while complex peptides can combine LPPS; semaglutide uses a hybrid route of recombinant expression followed by chemical modification.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• 603259.CH / 2359.HK WuXi AppTec

  Core beneficiary

  Strengths

  Rapid TIDES revenue growth, peptide output of about 58 tons in 2025, leading gross margin and EBIT margin, ROIC improving to about 38%, and a technology mix covering complex conjugation and sustainable processes.

  Weaknesses

  Peptide capacity is currently concentrated mainly in China, while globalization of overseas capacity is still in progress.

  Comparison

  Compared with Bachem, PolyPeptide, and EuroAPI, WuXi AppTec has significant advantages in scale, cost, capital efficiency, and growth speed.

  Risks

  Geopolitical escalation, loss of global ex-China market share, deterioration in service quality, and higher-than-expected failure rates for complex new therapeutic modalities.

• 002821.CH / 6821.HK Asymchem

  Potential share gainer

  Strengths

  Peptide business revenue grew 124% in 2025, with disclosed 45kL SPPS capacity and plans to increase it to 69kL in 2026; the technology mix covers multiple peptide conjugation categories.

  Weaknesses

  The peptide business revenue base remains significantly smaller than WuXi AppTec's, and ROIC and scale are still in the catch-up stage.

  Comparison

  Compared with Western specialized peptide companies, Asymchem is growing faster and has higher Chinese supply chain efficiency; compared with WuXi AppTec, its scale and margins are still weaker.

  Risks

  Capacity ramp-up below expectations, project losses, geopolitical risk, and lower-than-expected demand for metabolic peptides.

• 2269.HK WuXi Biologics

  Related covered company but not a core focus of this report's peptide CDMO thesis

  Strengths

  Biologics and ADC businesses could provide upside risk if they perform better than expected.

  Weaknesses

  Rated Market-Perform, with limited upside.

  Comparison

  Compared with WuXi AppTec and Asymchem, it is less directly tied to the report's main supply-side peptide CDMO theme.

  Risks

  Deterioration in service quality, geopolitical tensions, and higher-than-expected failure rates for new therapeutic modalities.

• Bachem / PolyPeptide / CordenPharma / EuroAPI

  Global peptide CDMO comparables

  Strengths

  They have specialized peptide manufacturing experience, regulatory track records, and manufacturing networks in Europe and the U.S.; among them, Bachem is relatively strong in process sustainability.

  Weaknesses

  Some companies are growing more slowly, have high capital expenditure intensity, and face ROIC pressure; PolyPeptide and EuroAPI are near break-even profitability.

  Comparison

  Western peers are superior to Chinese leaders in geographic diversification, but lag in the speed of scale expansion and cost efficiency.

  Risks

  Rising concentration in large-scale metabolic peptide projects may continue to dilute the share of traditional specialized peptide companies.

Key data

• Revenue of leading peptide CDMOsabout $1 billion to about $3 billionFrom 2021 to 2025, driven mainly by demand for GLP-1 and other metabolic peptides.
• WuXi AppTec TIDES revenueabout $120 million to $1.7 billionFrom 2021 to 2025, with market share increasing from 11% to 54%.
• WuXi AppTec 2025 peptide outputabout 58 tonsThe report believes tonnage output better reflects manufacturing scale than kL reactor volume.
• WuXi AppTec 2025 profitabilityabout 47% gross margin, 37% EBIT marginHigher than most global peptide CDMO peers.
• Asymchem 2025 peptide business revenueabout $152 million, up 124%The base is still small, but there is potential room for share gains after new capacity ramps up.
• Peptide manufacturing PMItypical peptide API about 13,000 to 14,000Significantly higher than the roughly 170 to 300 typical for small-molecule APIs, indicating high resource and solvent consumption intensity in peptide manufacturing.
• Development timeline comparisonWuXi AppTec peptide to IND about 4 to 6 months, to NDA about 12 to 15 months; Asymchem peptide to IND about 3 to 6 months, to NDA about 12 to 18 monthsThe report believes Chinese companies generally have shorter delivery cycles than Western peers.

Impact & implications

For investors, the supply-side benefits in peptide CDMOs are more likely to concentrate in platform companies capable of rapidly building and absorbing large-scale commercial capacity. WuXi AppTec has already established leadership in scale, margins, and ROIC, while Asymchem is in an accelerated catch-up phase; traditional Western specialized peptide companies still have customer trust and global site advantages, but if they cannot quickly improve large-batch capacity and capital efficiency, their share may continue to be diluted.

Risks

• Escalating geopolitical tensions could cause Chinese suppliers to lose share in global ex-China markets.
• Chinese leaders' peptide capacity is currently highly concentrated in China, and customers may worry about supply chain concentration.
• Deterioration in service quality or rising loss rates of integrated projects would weaken customer stickiness to CDMO platforms.
• If demand for GLP-1 and other metabolic peptides falls short of expectations, utilization of new capacity and ROIC could come under pressure.
• If failure rates for new therapeutic modalities such as peptides, ADCs, and bispecific antibodies are higher than expected, related CDMO revenue growth could be lower than expected.
• Peptide manufacturing has high resource and solvent consumption intensity, and pressure from environmental protection, green processes, and waste management could affect costs.

What to watch

• WuXi AppTec TIDES revenue growth, capacity utilization, and the construction progress of peptide manufacturing capacity in Singapore.
• Order intake and ramp-up speed after Asymchem expands capacity from 45kL to 69kL.
• Whether outsourcing demand for commercial GLP-1 and other metabolic peptide projects continues to exceed expectations.
• Whether global customers adjust China CDMO order allocation due to supply chain concentration or geopolitical factors.
• Utilization, margin, and ROIC recovery among Western peers such as Bachem, PolyPeptide, and CordenPharma after their capacity expansion.
• Commercial adoption of complex peptide conjugation, oligonucleotides, radionuclide conjugation, and green chemistry processes.